Health Condition 1: L088- Other specified local infections of the skin and subcutaneous tissue
Conditions
Interventions
Intervention1: INJECTION ACYCLOVIR: INJECTION ACYCLOVIR WILL BE GIVEN INTRALESIONALLY IN THE VIRAL WART LESION AT REGULAR INTERVALS
Control Intervention1: VACCINE MMR: VACCINE MMR WILL BE GIVEN INTRAL
Sponsors
Dr K Vidhi Jain
Eligibility
Inclusion criteria
Inclusion criteria: 1. Clinically diagnosed cases of plantar, palmar, periungual, and subungual warts 2. Age between 18 years and 65 years
Exclusion criteria
Exclusion criteria: 1.Known history of hypersensitivity to Acyclovir and MMR vaccine 2.Pregnancy and lactation 3.Immunocompromised status 4.Secondary infection/ulceration. 5.Patients with fever or signs of any inflammation or infection, meningitis, and convulsions. 6.Patients with any history of asthma, allergic skin disorders, hypersensitivity, or allergy to vaccines. 7.Patients with any history of concurrent systemic, or topical treatment of warts within the past 4 weeks. 8.Patients with genital/mucosal warts/plane warts.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| CHANGE IN SIZE AND NUMBER OF LESIONS AFTER TREATMENTTimepoint: BASELINE ( WEEK0), WEEK 2, WEEK 4, WEEK 6, WEEK 8 | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.PATIENT SATISFACTION SCALE BY VISUAL ANALOGUE SCALE 2.SIDE EFFECTS EVALUATIONTimepoint: BASELINE ( WEEK0), WEEK 2, WEEK 4, WEEK 6, WEEK 8 | — |
Countries
India
Contacts
Public ContactDr K Vidhi Jain
KLE ACADEMY OF HIGHER EDUCATION AND RESEARCH DEEMED TO BE UNIVERSITY, BELGAVI
Outcome results
None listed